NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00152178,The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC),https://clinicaltrials.gov/study/NCT00152178,,COMPLETED,"This controlled study is designed to evaluate the relapse-free survival of UFT + TAM compared with CMF + TAM. Patients are randomly assigned to receive either CMF + TAM or UFT + TAM within 6 weeks after surgery. To assess treatment efficacy, data on recurrence and survival will be collected for 5 years after surgery. To evaluate the safety, data on adverse events will be collected during treatment. Patients'quality of life will be assessed by means of a questionnaire.",NO,Breast Cancer,"DRUG: UFT (uracil, tegafur) and tamoxifen|DRUG: CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen","Relapse-free survival, recurrence and survival will be collected for 5 years after surgery","Overall survival, adverse events, and the quality of life, adverse events will be collected during treatment",,"Taiho Pharmaceutical Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,680,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,91023033,1996-07,2008-04,2008-08,2005-09-09,,2011-07-07,"Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-1-3, Nakamichi, Higashinari-ku, Osaka, Osaka, Japan",
